Syntis Bio key facts
as of Oct 2026- Developer of late-stage preclinical drugs designed for oral therapy for obesity, diabetes, and rare diseases.
- Syntis Bio is valued at approximately $67.0M as of Oct 2026, set at its early-stage round, Jun 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $48.4M across 3 recorded rounds; the latest was Early Stage VC ($25.0M) in Jun 2025.
- Notable investors include National Institutes of Health, Sky9 Capital, Safar Partners, Woori Venture Partners, BOLD Capital Partners — 12 tracked in total.
- Syntis Bio has filed 4 Form Ds with the SEC since 2022, most recently Jul 2025 ($25.0M sold to 12 investors).
- Status: Privately Held (backing).
Valued at $67.0M at its early-stage round, Jun 2025. Nothing has traded since.
- ·The complete investor list: 12 names
- ·Watch Syntis Bio: the Monday email on marks, rounds and moves
Syntis Bio funding rounds
3 roundsWho backs Syntis Bio
12+Syntis Bio valuation
Syntis Bio was valued at $67 million at its early-stage round in Jun 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Syntis Bio raised?
Syntis Bio has raised $48.4 million across 3 recorded rounds since 2022. The largest was a $6.3 million early-stage round in Dec 2024; the most recent was a $25 million early-stage round in Jun 2025.
Syntis Bio has filed 4 Form Ds with the SEC since 2022, most recently in Jul 2025 ($25 million sold to 12 investors).
Syntis Bio investors
12 investors are on record for Syntis Bio, including National Institutes of Health, Sky9 Capital, Safar Partners and Woori Venture Partners. The early-stage round in Jun 2025 drew 12 investors.
About Syntis Bio
Developer of late-stage preclinical drugs designed for oral therapy for obesity, diabetes, and rare diseases. The company's drug uses formulations for oral therapies that target specific tissues to leverage the small intestine's biology for metabolic and rare disease treatments through a daily nutrient-blocking pill using transient polymer coatings and gut-stable enzyme therapies, enabling researchers to treat patients within a broader disease category and with an effective options that mimic surgical benefits and reduce dietary restrictions.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2022
- Employees
- 17
- Website
- syntis.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.